Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers

Phase 3

Completed

• Conditions: Foot Ulcer, Diabetic
• Interventions: Drug: Placebo; Drug: Bemiparin

• Registration Number: NCT00448903
• Lead Sponsor: Rovi Pharmaceuticals Laboratories

Brief Summary

Chronic foot ulcers are a common, severe and expensive complication in patients with diabetes and often causes lower-extremity amputation. The aim of this study is to evaluate the effect of bemiparin as treatment of diabetic foot ulcers.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-03-15
• Study First Submitted QC: 2007-03-16
• Study First Posted: 2007-03-19
• Primary Completion: 2009-12
• Study Completion: 2010-04
• Status Verified: 2010-05
• Last Update Submitted: 2011-03-16
• Last Update Posted: 2011-03-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 329

Inclusion Criteria

• Patients over 18 years old who have given their informed consent to participate in the study.
• Patients with type I or II Diabetes Mellitus (ADA Criteria).
• Presence of chronic neuropathic inframalleolar diabetic foot ulcer (starting at least 2 months before), grade I or II on Wagner Classification, without significant improvement (reduction of ulcer area > or = 25%) within the past 15 days prior to inclusion.
• Ulcer size equal or bigger than 0.64 cm2 using the following formula: [Major axis] x [Minor axis]
• Ankle-brachial index (ABI) > or = 0,7

Exclusion Criteria

• Patients with clinical symptoms of limb-threatening or life-threatening infection
• Presence of bone exposure at the bottom of the ulcer and/or bone palpation by catheter and/or presence of radiological signs of pathological fractures and/or bone sequesters
• Ankle-brachial index (ABI) <0,7
• Subjects with arterial calcification (ABI > 1,3) with negative tibial and foot pulse that for any cause the Toe/Arm index (T/A) cannot be measured by plethysmography (photoplethysmography or strain-gauge)
• Subjects with arterial calcification (ABI > 1,3) with negative tibial and foot pulse and with T/A index < 0,55 measured by plethysmography (photoplethysmography or strain-gauge)
• Patients with hematological disorders, organic lesions susceptible to bleeding (e.g. active peptic ulcer, stroke, aneurysms), severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic blood pressure over 120 mmHg).
• Patients with severe renal failure (creatinine clearance <30 ml/min) or hepatic insufficiency (AST and/or ALT values >5 times the normal value established by the reference ranges of the local hospital laboratory).
• Patients with connective tissue disease
• Acute bacterial endocarditis or slow endocarditis.
• Patients with antithrombin deficit and C and S protein deficit.
• Patients with HbA1C > 12%.
• Women who are pregnant or breast-feeding, or with the possibility of becoming pregnant during the study.
• Known hypersensitivity to LMWH, heparin or substances of porcine origin.
• Patients with a history of heparin-induced thrombocytopenia.
• Patients on treatment with anticoagulant therapy at inclusion time or in the past 15 days.
• Patients on treatment with pentoxifiline at inclusion time or in the past 30 days.
• Patients on treatment with systemic corticosteroid or immunosuppressive therapy at inclusion time or in the past 3 months.
• Patients on treatment with beclapermin at inclusion time or in the past 15 days.
• Patients that have suffered a revascularization or endovascular surgery two months prior to inclusion
• Patients with a life expectancy less than 6 months.
• Patients that cannot complete the scheduled follow-up visits or are not able to complete the study period.
• Patients who are participating in another clinical trial or have done it in the past 30 days.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	Placebo	Placebo
A	Bemiparin	Bemiparin

Primary Outcome Measures

Name	Time	Method
total healing with intact skin or a significant improvement defined as a reduction of ulcer area > or = 50% or one degree reduction on Wagner Classification.	90 day

Secondary Outcome Measures

Name	Time	Method
incidence of major bleeding and the incidence of adverse events.	210 day

Trial Locations

Locations (6)

SERBIA; 🇷🇸 Belgrade, Serbia

CROATIA; 🇭🇷 Zagreb, Croatia

POLAND; 🇵🇱 Warsaw, Poland

ROMANIA; 🇷🇴 Timisoara, Romania

RUSSIA; 🇷🇺 St. Petersburg, Russian Federation

SPAIN; 🇪🇸 Madrid, Spain